Frequency of CYP2C9 polymorphisms in polynesian people and potential relevance to management of gout with benzbromarone

Joint Bone Spine

Volumn 81, Issue 2, 2014, Pages 160-163

  Roberts, Rebecca L ^a   Wallace, Mary C ^a   Wright, Daniel F B ^b   Cadzow, Murray ^b   Dalbeth, Nicola ^c   Jones, Peter B ^c   Stamp, Lisa K ^d   Harrison, Andrew A ^b   Black, Michael A ^b   Merriman, Tony R ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

CYP2C9 poor metabolizer allele; Hepatotoxicity; Uricosuric agent

Indexed keywords

BENZBROMARONE; CYTOCHROME P450 2C9; CYTOCHROME P450 2C9 2; CYTOCHROME P450 2C9 3; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ALLELE; ARTICLE; ASIAN; CAUCASIAN; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME POLYMORPHISM; GENE FREQUENCY; GENE SEQUENCE; GENOTYPE; GOUT; HOMOZYGOTE; HUMAN; HUMAN GENOME; MAJOR CLINICAL STUDY; MAORI; NEW ZEALAND; PACIFIC ISLANDER; SAMOA; START CODON; TONGA; COMPUTER MODEL; ETHNIC DIFFERENCE; ETHNIC GROUP; GENE ACTIVITY; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GENOME ANALYSIS; POLYNESIAN; POPULATION GROUP; SINGLE NUCLEOTIDE POLYMORPHISM;

CYP2C9 POOR METABOLIZER ALLELE; HEPATOTOXICITY; URICOSURIC AGENT;

ARYL HYDROCARBON HYDROXYLASES; BENZBROMARONE; EUROPEAN CONTINENTAL ANCESTRY GROUP; GOUT; GOUT SUPPRESSANTS; HUMANS; NEW ZEALAND; POLYMORPHISM, SINGLE NUCLEOTIDE; POLYNESIA;

EID: 84898546285     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2013.07.006     Document Type: Article

References (20)

1. Merriman T.R., Dalbeth N. The genetic basis of hyperuricaemia and gout. Joint Bone Spine 2011, 78:35-40. 10.1016/j.jbspin.2010.02.027.
2. McQueen F.M., Chhana A., Dalbeth N. Mechanisms of joint damage in gout: evidence from cellular and imaging studies. Nat Rev Rheumatol 2012, 8:173-181. 10.1038/nrrheum.2011.207.
3. Winnard D., Wright C., Taylor W.J., et al. National prevalence of gout derived from administrative health data in Aotearoa New Zealand. Rheumatology (Oxford) 2012, 51:901-909. 10.1093/rheumatology/ker361.
4. Dalbeth N., House M.E., Horne A., et al. The experience and impact of gout in Maori and Pacific people: a prospective observational study. Clin Rheumatol 2012, 10.1007/s10067-012-2110-5.
5. Dalbeth N., Kumar S., Stamp L., et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006, 33:1646-1650.
6. Lee M.H., Graham G.G., Williams K.M., et al. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?. Drug Saf 2008, 31:643-665.
7. Walter-Sack I., Gresser U., Adjan M., et al. Variation of benzbromarone elimination in man-a population study. Eur J Clin Pharmacol 1990, 39:173-176.
8. McDonald M.G., Rettie A.E. Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: formation of glutathione adducts from a catechol intermediate. Chem Res Toxicol 2007, 20:1833-1842. 10.1021/tx7001228.
9. Scott S.A., Khasawneh R., Peter I., et al. CombinedCYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 2010, 11:781-791. [2904527]. 10.2217/pgs.10.49.
10. Uchida S., Shimada K., Misaka S., et al. Benzbromarone pharmacokinetics and pharmacodynamics in different cytochrome P4502C9 genotypes. Drug Metab Pharmacokinet 2010, 25:605-610.
11. Hollis-Moffatt J.E., Phipps-Green A.J., Chapman B., et al. The renal urate transporterSLC17A1 locus: confirmation of association with gout. Arthritis Res Ther 2012, 14:R92. [3446466]. 10.1186/ar3816.
12. DePristo M.A., Banks E., Poplin R., et al. A framework for variation discovery and genotyping using next-generation DNAsequencing data. Nat Genet 2011, 43:491-498. [3083463]. 10.1038/ng.806.
13. Goecks J., Nekrutenko A., Taylor J., et al. Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences. Genome Biol 2010, 11:R86. [2945788]. 10.1186/gb-2010-11-8-r86.
14. Zhou S.F., Zhou Z.W., Huang M. Polymorphisms of human cytochrome P4502C9 and the functional relevance. Toxicology 2010, 278:165-188. 10.1016/j.tox.2009.08.013.
15. Kramer M.A., Rettie A.E., Rieder M.J., et al. NovelCYP2C9 promoter variants and assessment of their impact on gene expression. Mol Pharmacol 2008, 73:1751-1760. [2413059]. 10.1124/mol.107.044149.
16. Lee S.J., Jang Y.J., Cha E.Y., et al. A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients. Br J Clin Pharmacol 2010, 70:213-221. [2911551]. 10.1111/j.1365-2125.2010.03688.x.
17. Perera M.A., Gamazon E., Cavallari L.H., et al. The missing association: sequencing-based discovery of novelSNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin Pharmacol Ther 2011, 89:408-415. 10.1038/clpt.2010.322.
18. Veenstra D.L., Blough D.K., Higashi M.K., et al. CYP2C9haplotype structure in European American warfarin patients and association with clinical outcomes. Clin Pharmacol Ther 2005, 77:353-364. 10.1016/j.clpt.2005.01.019.
19. Takahashi H., Ieiri I., Wilkinson G.R., et al. 5'-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients. Blood 2004, 103:3055-3057. 10.1182/blood-2003-07-2521.
20. Xiong Y., Wang M., Fang K., et al. A systematic genetic polymorphism analysis of the CYP2C9gene in four different geographical Han populations in mainland China. Genomics 2011, 97:277-281. 10.1016/j.ygeno.2010.11.004.